BC
Birchview Capital Portfolio holdings
AUM
$101M
This Quarter Return
+7.33%
1 Year Return
+34.62%
3 Year Return
+103.2%
5 Year Return
+107.72%
10 Year Return
+352.1%
AUM
$123M
AUM Growth
+$123M
(+6.4%)
Cap. Flow
+$4.41M
Cap. Flow
% of AUM
3.59%
Top 10 Holdings %
Top 10 Hldgs %
65.43%
Holding
71
New
10
Increased
12
Reduced
8
Closed
3
Top Buys
| 1 |
Prothena Corp
PRTA
|
$1.32M |
| 2 |
DocGo
DCGO
|
$1.06M |
| 3 |
Treace Medical Concepts
TMCI
|
$692K |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$673K |
| 5 |
Castle Biosciences
CSTL
|
$533K |
Top Sells
| 1 |
Alphatec Holdings
ATEC
|
$1.29M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$1.14M |
| 3 |
Coherus Oncology, Inc. Common Stock
CHRS
|
$400K |
| 4 |
Progyny
PGNY
|
$369K |
| 5 |
Elutia
ELUT
|
$358K |
Sector Composition
| 1 | Healthcare | 96.88% |
| 2 | Energy | 3.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Ultragenyx Pharmaceutical
RARE
$2.89B
| $673K | 0.55% |
+16,000
| New | +$673K |
|
27
Xencor
XNCR
$580M
| $597K | 0.49% |
26,000
+13,700
| +111% | +$315K |
|
28
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $593K | 0.48% |
30,000
| – | – |
|
29
KalVista Pharmaceuticals
KALV
$678M
| $567K | 0.46% |
67,000
-15,000
| -18% | -$127K |
|
|
30
Alphatec Holdings
ATEC
$2.35B
| $532K | 0.43% |
58,000
-140,000
| -71% | -$1.29M |
|
31
Candel Therapeutics
CADL
$318M
| $521K | 0.42% |
+60,000
| New | +$521K |
|
32
Wave Life Sciences
WVE
$1.53B
| $495K | 0.4% |
40,000
| – | – |
|
33
Inhibrx
INBX
$408M
| $494K | 0.4% |
32,110
| – | – |
|
34
Halozyme
HALO
$8.56B
| $478K | 0.39% |
10,000
| – | – |
|
35
Cytokinetics
CYTK
$4.23B
| $470K | 0.38% |
10,000
| – | – |
|
36
Apellis Pharmaceuticals
APLS
$3.48B
| $447K | 0.36% |
14,000
| – | – |
|
37
Sarepta Therapeutics
SRPT
$1.78B
| $426K | 0.35% |
3,500
+1,000
| +40% | +$122K |
|
38
Outset Medical
OM
$247M
| $409K | 0.33% |
368,766
+358,766
| +3,588% | +$398K |
|
39
Xenon Pharmaceuticals
XENE
$2.98B
| $392K | 0.32% |
10,000
| – | – |
|
|
AXDX
40
DELISTED
Accelerate Diagnostics
AXDX
| $390K | 0.32% |
325,239
| – | – |
|
41
TELA Bio
TELA
$70.5M
| $378K | 0.31% |
+125,000
| New | +$378K |
|
|
SWTX
42
DELISTED
SpringWorks Therapeutics
SWTX
| $361K | 0.29% |
10,000
| – | – |
|
43
uniQure
QURE
$896M
| $353K | 0.29% |
20,000
| – | – |
|
44
Pulmonx
LUNG
$69.7M
| $346K | 0.28% |
+51,000
| New | +$346K |
|
45
Scholar Rock
SRRK
$3.14B
| $346K | 0.28% |
+8,000
| New | +$346K |
|
46
Axsome Therapeutics
AXSM
$6.05B
| $338K | 0.28% |
4,000
| – | – |
|
47
BioCryst Pharmaceuticals
BCRX
$1.74B
| $301K | 0.24% |
40,000
| – | – |
|
48
Atara Biotherapeutics
ATRA
$84.6M
| $293K | 0.24% |
+22,000
| New | +$293K |
|
49
Arvinas
ARVN
$568M
| $288K | 0.23% |
15,000
| – | – |
|
50
Karyopharm Therapeutics
KPTI
$61.7M
| $284K | 0.23% |
419,832
-50,000
| -11% | -$33.8K |
|